Phase II trial of bi-weekly cetuximab for recurrent or metastatic colorectal cancer

ABSTRACT: Interventions: bi weekly cetuximab Primary outcome(s): Disease control rate Study Design: Single arm Non-randomized

DISEASE(S): Recurrent Or Metastatic Colorectal Cancer

PROVIDER: 2621883 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR